Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

762.63 +24.29 (+3.29%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,158,585
Open	726.69
Bid (Size)	755.00 (40)
Ask (Size)	762.63 (40)
Prev. Close	738.34
Today's Range	724.79 - 764.75
52wk Range	541.00 - 821.11
Shares Outstanding	91,779,465
Dividend Yield	0.49%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation

July 31, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

REGN Q2 Deep Dive: Pipeline Progress and Product Momentum Drive Outperformance

July 31, 2026

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 16.7% year on year to $4.29 billion....

Via StockStory

Performance

YTD	-1.8%	-1.8%
1 Month	+22.1%	+22.1%
3 Month	+8.7%	+8.7%
6 Month	+2.9%	+2.9%
1 Year	+39.8%	+39.8%

More News

Regeneron (REGN) Q2 2026 Earnings Call Transcript ↗

July 30, 2026

Via The Motley Fool

Regeneron Pharmaceuticals Q2 Earnings Call Highlights ↗

July 30, 2026

Via MarketBeat

Regeneron Pharmaceuticals (NASDAQ:REGN) Surges After Crushing Q2 Estimates with Revenue and EPS Beat ↗

July 30, 2026

Via Chartmill

Regeneron Pharmaceuticals (NASDAQ:REGN): A Quality Value Stock with Decent Growth and a Clear Discount ↗

July 24, 2026

Via Chartmill

Regeneron’s (NASDAQ:REGN) Q2 CY2026: Strong Sales

July 30, 2026

Via StockStory

Regeneron Reports Second Quarter 2026 Financial and Operating Results

July 30, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

July 29, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Regeneron (REGN) To Report Earnings Tomorrow: Here Is What To Expect

July 28, 2026

Via StockStory

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN

July 28, 2026

From Pomerantz LLP

Via GlobeNewswire

3 Cash-Heavy Stocks with Questionable Fundamentals

July 27, 2026

Via StockStory

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 24, 2026

From Schall Law

Via GlobeNewswire

REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

July 23, 2026

From Levi & Korsinsky, LLP

Via Business Wire

Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against REGN

July 23, 2026

Via Newsfile

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)

July 23, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

July 23, 2026

From Faruqi & Faruqi, LLP

Via Business Wire

REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

July 22, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law

July 21, 2026

From Bleichmar Fonti & Auld LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN

July 21, 2026

From Pomerantz LLP

Via GlobeNewswire

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 21, 2026

From Schall Law

Via GlobeNewswire

REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

July 20, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN

July 18, 2026

From DJS Law Group

Via Business Wire

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 17, 2026

From The Schall Law Firm

Via Business Wire

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 17, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?

Yes, Regeneron Pharmaceuticals is publicly traded.

What exchange does Regeneron Pharmaceuticals trade on?

Regeneron Pharmaceuticals trades on the Nasdaq Stock Market

What is the ticker symbol for Regeneron Pharmaceuticals?

The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market

What is the current price of Regeneron Pharmaceuticals?

The current price of Regeneron Pharmaceuticals is 762.63

When was Regeneron Pharmaceuticals last traded?

The last trade of Regeneron Pharmaceuticals was at 07/31/26 04:00 PM ET

What is the market capitalization of Regeneron Pharmaceuticals?

The market capitalization of Regeneron Pharmaceuticals is 69.99B

How many shares of Regeneron Pharmaceuticals are outstanding?

Regeneron Pharmaceuticals has 70B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.